Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.
Hepatic and renal insufficiency due to co-infection, alcoholism, diabetes mellitus, family history, adverse effects of antiretrovirals and other factors are commonly seen in HIV-infected patients. Therefore, the use of antiretrovirals in this patient setting requires attention to the pharmacokinetic issues that clinicians must consider when prescribing highly active antiretroviral therapy for these patients. This review summarizes the current knowledge of the use of antiretrovirals in patients with hepatic or renal impairment, and makes dosing recommendations for this subpopulation of HIV-infected patients.
McCabe
Sarah M
SM
Department of Pharmacy Practice and Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.
Ma
Qing
Q
Slish
Judianne C
JC
Catanzaro
Linda M
LM
Sheth
Neha
N
DiCenzo
Robert
R
Morse
Gene D
GD
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D023241:Antiretroviral Therapy, Highly Active; D016903:Drug Monitoring; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications*; D008107:Liver Diseases / Q000150:complications*; D011485:Protein Binding
D019380:Anti-HIV Agents